- SILO recently provided status update on its sponsored clinical trial with UCSF examining psilocybin’s effects on inflammation
- Targeted patient populations from study may provide support for development and use of psilocybin as a therapeutic to treat inflammatory conditions
- Data collection from all study groups expected by April 2023
- SILO additionally evaluating its ketamine formulation through its partnership agreement with Zylö Therapeutics
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company that fuses traditional medicine with psychedelics, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation.
Research into psychedelics like psilocybin has recently experienced a renaissance, specifically for treating depression, addiction, anxiety, obsessive-compulsive disorder, and inflammatory diseases (
https://ibn.fm/vnsO7). Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a therapeutic by evaluating the effects of the compound on patients suffering from inflammatory disorders, including Parkinson’s disease, bipolar disorder, and chronic pain.
“The UCSF research team is making progress on the clinical trial,” said Eric Weisblum, Chief Executive Officer of Silo Pharma (
https://ibn.fm/h7cAA). “The data gathered from these studies could uncover the role of inflammatory activity on such conditions as Parkinson’s, bipolar disorder, and chronic pain. Utilizing psilocybin in this study in a regimented dosing pattern, we hope to gain significant data both in mechanism of action and potential biomarker for personalization of psilocybin therapy. The targeted patient populations from the study could provide support for the development and use of psilocybin as a therapeutic coupled with our novel homing peptides and topical technology.”
The clinical study comprises preparation therapy, two separate dosing sessions with psilocybin, and integration therapy for the three patient populations afflicted with Parkinson’s disease, bipolar disorder, and chronic pain. Blood samples are collected from each patient at four points: one at baseline before treatment begins, one at 24 hours following both dosing sessions, and one after 30 days during a follow-up session. Data collection from the study is expected to be completed by April 2023 for all three patient populations.
In addition to its partnership with UCSF, Silo Pharma is also evaluating its ketamine formulation, designated as SPC-14, through a joint partnership agreement with Columbia University (
https://ibn.fm/9OQtD). The company initially entered a sponsored pact with the university in October 2021 and has recently extended the contract to continue research for SPC-14 and SPC-15, a targeted therapeutic for stress-induced anxiety disorders (
https://ibn.fm/969lZ).
Silo Pharma Inc. is fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, rheumatoid arthritis, and other rare neurological disorders. The company partners with leading institutions such as Columbia University, the University of California San Francisco (“UCSF”), and the University of Maryland, Baltimore (“UMB”) to develop treatments the company believes will transform healthcare and improve patient outcomes.
For more information, visit the company’s website at
www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at
https://ibn.fm/SILO
